DOP2015000132A - Moduladores selectivos del receptor de andrógenos novedosos - Google Patents

Moduladores selectivos del receptor de andrógenos novedosos

Info

Publication number
DOP2015000132A
DOP2015000132A DO2015000132A DO2015000132A DOP2015000132A DO P2015000132 A DOP2015000132 A DO P2015000132A DO 2015000132 A DO2015000132 A DO 2015000132A DO 2015000132 A DO2015000132 A DO 2015000132A DO P2015000132 A DOP2015000132 A DO P2015000132A
Authority
DO
Dominican Republic
Prior art keywords
branched chain
chain alkyl
straight
hydrogen
independently hydrogen
Prior art date
Application number
DO2015000132A
Other languages
English (en)
Inventor
Patrick Robert Verhoest
James Thomas Anderson
Eugene Lvovich Piatnitski Chekler
Edmund L Ellsworth
Bruce Kipp Erikcson
Adam Matthew Gilbert
Anthony P Ricketts
David P Thompson
Rayomand Jal Unwalla
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49955433&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2015000132(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of DOP2015000132A publication Critical patent/DOP2015000132A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN COMPUESTO DE LA FÓRMULA 1, 2 Ó 3: EN DONDE A ES N O –CR0––, DONDE R0 ES HIDRÓGENO, ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ETC., Z ES –CRE––, O, –N––, DONDE RE ES HIDRÓGENO, ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ETC.; R1 ES HIDRÓGENO, ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ETC.; R2 SON INDEPENDIENTEMENTE HIDRÓGENO O ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6; R3 Y R4 SON INDEPENDIENTEMENTE HIDRÓGENO, ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ETC.; R5 Y R6 SON INDEPENDIENTEMENTE HIDRÓGENO O ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ETC.; R8 ES HIDRÓGENO, ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ETC.; R9 Y R10 SON INDEPENDIENTEMENTE HIDRÓGENO O ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ETC.; Q ES ––CO––, ––(CH2)Q––, ––(CHRS)Q––, O –(CRSRT)Q––, DONDE RS Y RT SON INDEPENDIENTEMENTE ALQUILO DE CADENA LINEAL O RAMIFICADA DE C1-C6, ARILO, ALQUILARILO, HETEROARILO O ALQUILHETEROARILO; EN DONDE Q ES 0, 1, 2, O 3; Y, DONDE N ES 0, 1, 2, 3, 4 Ó 5; O, UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LOS MISMOS, PARA COMPOSICIONES QUE CONTIENEN TALES COMPUESTOS; Y PARA LOS USOS DE TALES COMPUESTOS EN EL TRATAMIENTO DE DIVERSAS ENFERMEDADES, PARTICULARMENTE, AQUELLAS AFECTADAS O MEDIADAS POR EL RECEPTOR DE ANDRÓGENOS.
DO2015000132A 2012-12-03 2015-06-03 Moduladores selectivos del receptor de andrógenos novedosos DOP2015000132A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261732617P 2012-12-03 2012-12-03

Publications (1)

Publication Number Publication Date
DOP2015000132A true DOP2015000132A (es) 2015-12-31

Family

ID=49955433

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000132A DOP2015000132A (es) 2012-12-03 2015-06-03 Moduladores selectivos del receptor de andrógenos novedosos

Country Status (34)

Country Link
US (1) US9328104B2 (es)
EP (1) EP2925725B1 (es)
JP (1) JP6039100B2 (es)
KR (1) KR101745225B1 (es)
CN (1) CN104854093B (es)
AP (1) AP2015008444A0 (es)
AR (1) AR093697A1 (es)
AU (1) AU2013353723B2 (es)
BR (1) BR112015011897B1 (es)
CA (1) CA2891234C (es)
CL (1) CL2015001495A1 (es)
CO (1) CO7400864A2 (es)
CR (1) CR20150290A (es)
CU (1) CU20150054A7 (es)
DK (1) DK2925725T3 (es)
DO (1) DOP2015000132A (es)
EA (1) EA026562B1 (es)
ES (1) ES2609596T3 (es)
HK (1) HK1209744A1 (es)
IL (1) IL239076B (es)
MA (1) MA38114A1 (es)
MD (1) MD20150049A2 (es)
MX (1) MX368898B (es)
MY (1) MY176727A (es)
NZ (1) NZ707752A (es)
PE (1) PE20151158A1 (es)
PH (1) PH12015501215A1 (es)
SG (1) SG11201503580WA (es)
TN (1) TN2015000237A1 (es)
TW (1) TWI518083B (es)
UA (1) UA110766C2 (es)
UY (1) UY35158A (es)
WO (1) WO2014087298A1 (es)
ZA (1) ZA201503517B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3143019T (pt) 2014-05-15 2021-01-28 Pfizer Forma cristalina de 6-[(4r)-4-metil-1,2-dióxido-1,2,6- tiadiazinan-2-il]isoquinolina-1-carbonitrilo
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107573270B (zh) * 2017-09-29 2019-11-29 河南师范大学 一种α-甲酰基吡咯烷类化合物的合成方法
CN110372628B (zh) * 2019-07-09 2021-04-02 武汉大学 内磺酰胺类化合物及其制备方法
US20220315568A1 (en) * 2019-09-12 2022-10-06 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2023275715A1 (en) * 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE638650C (de) 1934-06-08 1936-11-20 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von 3, 4-Dioxyphenylmonoalkylaminobutanolen-1
US2482055A (en) 1948-02-11 1949-09-13 American Cyanamid Co Aureomycin and preparation of same
US2715141A (en) 1952-03-27 1955-08-09 Delmar Chem Optically active isopropyl arterenol
US3377364A (en) 1957-09-23 1968-04-09 Upjohn Co 6-methyl-17alpha-hydroxyprogesterone, the lower fatty acid 17-acylates and methods for producing the same
US3332940A (en) 1959-08-28 1967-07-25 British Drug Houses Ltd Process for the preparation of 17alpha-acyloxy-6-methyl-16-methylene-4, 6-pregnadiene-3, 20-diones and intermediates obtained therefrom
US3359287A (en) 1959-11-16 1967-12-19 Upjohn Co 16-methylene-17alpha-hydroxy progesterones and derivatives thereof
DE1275069B (de) 1960-02-15 1968-08-14 Boehringer Sohn Ingelheim 1-(3', 5'-Dihydroxyphenyl)-1-hydroxy-2-isopropylaminoalkane und Verfahren zu ihrer Herstellung
DE1158966B (de) 1961-04-29 1963-12-12 Schering Ag Verfahren zur Herstellung von 6-Chlor-1, 2ª‡-methylen-í¸-17ª‡-hydroxyprogesteronestern
NL130078C (es) 1963-06-11
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
DE1618005A1 (de) 1966-09-22 1971-09-09 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen Amino-dihalogen-phenyl-aethylaminen
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US4138581A (en) 1969-04-01 1979-02-06 Sterling Drugs Inc. 3(Hydroxy or hydroxymethyl)-4(hydroxy)-α-(aminomethyl)benzyl alcohols
US3705169A (en) 1970-11-05 1972-12-05 Smith Kline French Lab Hydroxyphenyl-2-piperidinylcarbinols
US3763232A (en) 1971-01-11 1973-10-02 Smith Kline French Lab Alpha-aminoalkyl-4-hydroxy-3-ureidobenzyl alcohols
US3700681A (en) 1971-02-16 1972-10-24 Pfizer 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines
BE788737A (fr) 1971-09-13 1973-01-02 Hokuriku Pharmaceutical Procede de preparation de derives de l'alcool o-chlorobenzylique
BE789629A (fr) 1971-10-05 1973-04-03 Sandoz Sa Nouveaux derives de la pleuromutiline, leur preparation et leurapplication en therapeutique
US3919290A (en) 1972-10-03 1975-11-11 Sandoz Ltd Substituted 14-desoxy-mutilins
US3839557A (en) 1972-01-24 1974-10-01 Lilly Co Eli Antibiotics monensin and a204 for improving ruminant feed efficiency
US3939265A (en) 1972-05-10 1976-02-17 Jean Andre Grandadam Novel zootechnical compositions
US4119710A (en) 1972-12-18 1978-10-10 Boehringer Ingelheim Gmbh Bronchospasmolytic 1-(p-amino-phenyl)-2-amino-ethanols-(1) and salts
US4026897A (en) 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
US4048268A (en) 1975-02-19 1977-09-13 Eli Lilly And Company Stabilization method
US3987194A (en) 1975-05-12 1976-10-19 E. R. Squibb & Sons, Inc. Use of pleuromutilin derivatives for the treatment of swine dysentery
US3995027A (en) 1975-06-04 1976-11-30 Eli Lilly And Company Anti-viral method in animals
FR2388560A1 (fr) 1977-04-27 1978-11-24 Roussel Uclaf Nouvelles compositions zootechniques renfermant d'une part le zeranol et d'autre part un steroide 4,9,11 trienique
US4154748A (en) 1978-01-20 1979-05-15 The Upjohn Company Phosphate catalyzed acylation of steroidal tertiary alcohols
US4283388A (en) 1979-12-26 1981-08-11 Eli Lilly And Company Method for treating colibacillosis in pigs with tylosin apramycin compositions
DE3163871D1 (en) 1980-07-09 1984-07-05 Draco Ab 1-(dihydroxyphenyl)-2-amino-ethanol derivatives; preparation, compositions and intermediates
US5643967A (en) 1983-01-31 1997-07-01 Eli Lilly And Company Growth promotion
IE60964B1 (en) 1986-12-11 1994-09-07 Roussel Uclaf Zootechnical compositions containing a beta-adrenergic
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
DE4014252A1 (de) 1990-05-04 1991-11-07 Boehringer Ingelheim Vetmed Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer
GB9107196D0 (en) 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AUPO776897A0 (en) 1997-07-09 1997-07-31 Csl Limited A method of achieving production gains in livestock and agents useful for same
JP4426792B2 (ja) * 2002-08-12 2010-03-03 武田薬品工業株式会社 縮合ベンゼン誘導体および用途
JP2007505164A (ja) 2003-06-10 2007-03-08 スミスクライン ビーチャム コーポレーション アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての１−アミノナフタレン類
MXPA06001751A (es) * 2003-08-22 2006-05-12 Ligand Pharm Inc Derivados de 6-cicloamino-2-quinolinona como compuestos moduladores de receptor de androgeno.
AU2005247405A1 (en) * 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
PT2222636E (pt) * 2007-12-21 2013-07-16 Ligand Pharm Inc Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
MX2010009162A (es) * 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.

Also Published As

Publication number Publication date
CN104854093B (zh) 2016-10-12
US20140155390A1 (en) 2014-06-05
CL2015001495A1 (es) 2015-10-02
CN104854093A (zh) 2015-08-19
CO7400864A2 (es) 2015-09-30
TN2015000237A1 (fr) 2016-10-03
IL239076B (en) 2018-10-31
WO2014087298A4 (en) 2014-08-21
CR20150290A (es) 2015-07-09
IL239076A0 (en) 2015-07-30
BR112015011897B1 (pt) 2021-11-03
ZA201503517B (en) 2017-11-29
PH12015501215B1 (en) 2015-08-17
HK1209744A1 (en) 2016-04-08
MY176727A (en) 2020-08-20
NZ707752A (en) 2020-01-31
AR093697A1 (es) 2015-06-17
UY35158A (es) 2014-07-31
AP2015008444A0 (en) 2015-05-31
SG11201503580WA (en) 2015-06-29
CA2891234C (en) 2017-03-07
TW201434833A (zh) 2014-09-16
KR101745225B1 (ko) 2017-06-08
AU2013353723A1 (en) 2015-05-21
EA026562B1 (ru) 2017-04-28
PH12015501215A1 (en) 2015-08-17
EP2925725A1 (en) 2015-10-07
MA38114A1 (fr) 2017-12-29
PE20151158A1 (es) 2015-08-14
BR112015011897A2 (pt) 2017-07-11
EP2925725B1 (en) 2016-11-09
US9328104B2 (en) 2016-05-03
CU20150054A7 (es) 2015-12-23
JP6039100B2 (ja) 2016-12-07
TWI518083B (zh) 2016-01-21
MX2015006987A (es) 2015-09-23
MD20150049A2 (ro) 2015-11-30
JP2016501214A (ja) 2016-01-18
ES2609596T3 (es) 2017-04-21
DK2925725T3 (en) 2017-01-16
KR20150090247A (ko) 2015-08-05
CA2891234A1 (en) 2014-06-12
WO2014087298A1 (en) 2014-06-12
UA110766C2 (uk) 2016-02-10
MX368898B (es) 2019-10-21
AU2013353723B2 (en) 2018-02-22
EA201590757A1 (ru) 2015-11-30

Similar Documents

Publication Publication Date Title
DOP2015000132A (es) Moduladores selectivos del receptor de andrógenos novedosos
PH12017501192B1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
CR20140042A (es) Indazoles
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
MX2016015467A (es) Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos.
MY186165A (en) New bicyclic dihydroquinoline-2-one derivatives
PE20150623A1 (es) Moduladores de la ruta del complemento y usos de los mismos
MX2013012211A (es) Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato.
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
DOP2014000178A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2
CY1119296T1 (el) Ενωση δικαρβοξυλικου οξεος
ECSP13012366A (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo
PH12014502285A1 (en) Anti-malarial agents
CR20160030A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20130476A (es) Derivados de pirazolidin-3-ona
ECSP13012735A (es) Nuevo procedimiento de síntesis de la agomelatina
CR20130005A (es) Agentes terapéuticos 976
ECSP14011505A (es) Derivados de bencil sulfonamida útiles como inhibidores de mogat-2
UY35743A (es) Procedimiento de síntesis para la preparación de analogos c1-ceto macrociclicos de halicondrina b e intermediarios útiles en el mismo
CO6731102A2 (es) Nuevo procedimiento de síntesis de la agomelatina